It has been reported in the literature that RUNX2 is able to recruit the NuRD (MTA1)/CRL4B complex and accelerate breast cancer progression and bone metastasis [18] and RUNX2 is also associated with breast cancer drug resistance [19]. This evidence concerns the gene RUNX2 and breast carcinoma.